TY - JOUR
T1 - Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection
AU - Ardito, Francesco
AU - Razionale, Francesco
AU - Salvatore, Lisa
AU - Cenci, Tonia
AU - Vellone, Maria
AU - Basso, Michele
AU - Panettieri, Elena
AU - Calegari, Maria Alessandra
AU - Tortora, Giampaolo
AU - Martini, Maurizio
AU - Giuliante, Felice
PY - 2021
Y1 - 2021
N2 - If KRAS mutation status of primary colorectal tumor is representative of corresponding
colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have
reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess
the incidence of discordance and its impact on overall survival (OS) in a homogenous group of
patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal
tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate
was 15.9%. Its incidence varied according to the time interval between the two mutation analyses
(p = 0.025; Pearson correlation = 0.2) and it was significantly higher during the first 6 months from
the time of primary tumor evaluation. On multivariable analysis, type of discordance (wild‐type in
primary tumor, mutation in CRLM) was the strongest predictor of poor OS (p < 0.001). At
multivariable logistic regression analysis, the number of CRLM >3 was an independent risk factor
for the risk of KRAS discordance associated with the worst prognosis (OR = 4.600; p = 0.047). Results
of our study suggested that, in the era of precision medicine, possibility of KRAS discordance
should be taken into account within multidisciplinary management of patients with metastatic
colorectal cancer.
AB - If KRAS mutation status of primary colorectal tumor is representative of corresponding
colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have
reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess
the incidence of discordance and its impact on overall survival (OS) in a homogenous group of
patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal
tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate
was 15.9%. Its incidence varied according to the time interval between the two mutation analyses
(p = 0.025; Pearson correlation = 0.2) and it was significantly higher during the first 6 months from
the time of primary tumor evaluation. On multivariable analysis, type of discordance (wild‐type in
primary tumor, mutation in CRLM) was the strongest predictor of poor OS (p < 0.001). At
multivariable logistic regression analysis, the number of CRLM >3 was an independent risk factor
for the risk of KRAS discordance associated with the worst prognosis (OR = 4.600; p = 0.047). Results
of our study suggested that, in the era of precision medicine, possibility of KRAS discordance
should be taken into account within multidisciplinary management of patients with metastatic
colorectal cancer.
KW - KRAS mutation status
KW - colorectal liver metastases
KW - colorectal tumor
KW - precision medicine
KW - KRAS mutation status
KW - colorectal liver metastases
KW - colorectal tumor
KW - precision medicine
UR - http://hdl.handle.net/10807/178685
U2 - 10.3390/cancers13092148
DO - 10.3390/cancers13092148
M3 - Article
SN - 2072-6694
VL - 13
SP - 2148
EP - 2163
JO - Cancers
JF - Cancers
ER -